BPC-157

BPC-157 (Body Protection Compound 157) is a synthetic peptide, a chain of 15 amino acids derived from a protective protein naturally found in human gastric juice. Its primary use case is accelerating the healing of injuries, particularly tendons, ligaments, and joints that are stalled or slow to recover. It's also widely used for gut healing (NSAID damage, IBS, leaky gut). May also support neural recovery by ensuring proper nutrient delivery and waste removal across the BBB

The research base is almost entirely animal studies, but the findings are consistent enough and the mechanisms well-understood enough that BPC-157 has become one of the more widely used peptides in both clinical and self-administered settings. A 2025 systematic review screened 544 articles and included 36 studies, 35 preclinical and only 1 clinical. Only three small human studies exist as of early 2026: a 2021 case series on chronic knee pain (14 of 16 patients reported significant relief at 6 to 12 months), a 2024 pilot study on interstitial cystitis in 12 women (10 of 12 reported complete symptom resolution), and a 2025 IV safety pilot (up to 20 mg in 2 healthy adults with no adverse effects). None had control groups, and all came from the same research group, so they're encouraging but far from definitive. A Phase I trial from 2015 with 42 volunteers was cancelled and never published, which means the foundational pharmacokinetic data that would normally inform human dosing still doesn't exist. The doses people use today are extrapolated from animal studies.

A 2025 scoping review also flagged potential publication bias in BPC-157 research, meaning negative findings may be going unpublished. This doesn't invalidate the positive data, but the evidence base may look more uniformly favourable than it actually is.

The compound works through multiple parallel pathways simultaneously:

Angiogenesis and vascular repair: BPC-157 consistently promotes new blood vessel formation in damaged tissue and restores blood flow to injured areas. It upregulates VEGF and VEGFR2, and one of its most reproducible effects in animal models is the reversal of anastomosis failure, reconnecting severed or damaged vessels that would otherwise fail to heal.

Growth hormone receptor upregulation in tendons: BPC-157 directly upregulates growth hormone receptors on tendon fibroblasts. This is one of the primary reasons it's used for tendon and ligament injuries. It makes local tissue more responsive to growth hormone already circulating, accelerating the fibroblast activity responsible for tendon repair. One study on transected Achilles tendons in rats showed full functional recovery when treated with BPC-157, including restored tensile strength and structure.

Bone healing: Preclinical models show BPC-157 accelerates fracture healing and improves bone density in treated subjects, broadening its relevance beyond soft tissue to skeletal injuries.

Nitric oxide modulation: BPC-157 interacts with the nitric oxide system, which underpins a lot of its vascular, anti-inflammatory, and gut-protective effects. It appears to both stabilise NO production and counteract NO-related damage depending on context.

CNS and neurotransmitter effects: BPC-157 interacts with dopaminergic and serotonergic systems. Research in rats shows it can counteract dopamine depletion, reduce dopamine receptor sensitisation from chronic stimulant exposure, and modulate serotonin activity. This likely explains the mood and anxiolytic effects some users report.

Gut cytoprotection: In the gut specifically, BPC-157 protects the mucosal lining from damage caused by NSAIDs, alcohol, and stress. It accelerates healing of intestinal fistulas, anastomosis sites, and inflammatory lesions. Studies have shown it speeds healing of IBD-like lesions and restores gut motility disrupted by inflammation. The 2024 interstitial cystitis study mentioned above is notable because it's one of the few human data points and was conducted entirely on women (ages 39 to 76), showing strong results for a condition that disproportionately affects women.

Systemic anti-inflammatory: Beyond the gut, BPC-157 downregulates inflammatory cytokines broadly and reduces oxidative stress in damaged tissue, without suppressing immune function systemically.

Dosage:

200 to 500 mcg per day subcutaneous or intramuscular injection. Half-life is under 30 minutes, so twice-daily dosing (e.g. 250 mcg morning and evening) is common for acute injuries to keep plasma levels more stable

For localised injuries (tendons, ligaments, joints), inject close to but not directly into the injury site for better local concentration

Typical cycle: 4 to 8 weeks on, then a break. Some run lower doses (200 mcg/day) continuously for longer periods

Frequently stacked with TB-500 (Thymosin Beta-4) for injury recovery. BPC-157 handles localised repair and vascular regrowth, TB-500 handles broader tissue remodelling and cell migration. The combination covers more of the healing cascade than either alone

Oral: 250 to 500 mcg per day on an empty stomach, sometimes up to 1,000 mcg/day to compensate for lower bioavailability. Oral is primarily effective for gut and mucosal healing. For purely GI issues (IBS, leaky gut, NSAID damage, ulcers), oral is sufficient and avoids the inconvenience of injecting. For women using NSAIDs chronically (menstrual pain, endometriosis, autoimmune conditions), oral BPC-157 is particularly relevant for gut mucosal protection

No hormonal interactions. Does not affect estrogen, progesterone, HPA, or HPG axis. No female-specific dose adjustment needed, dosing is the same across all groups. Non-suppressive and non-hepatotoxic.

Here's what you can expect:

For injury recovery (the most commonly reported and best-supported use): most people notice a meaningful reduction in pain and inflammation within the first 1 to 2 weeks. Structural repair, meaning actual tendon, ligament, or muscle tissue healing, takes longer, typically 4 to 8 weeks depending on severity. Injuries that have been stalled for months often respond faster than expected, likely because BPC-157 restores the vascular supply that chronic injuries tend to lose. Acute injuries respond faster than chronic ones. The 2021 knee pain study supports this timeline, with most patients reporting significant pain relief sustained at 6 to 12 months.

For gut healing: improvement in symptoms like bloating, cramping, reflux, and general gut sensitivity is often reported within 2 to 4 weeks. People using it post-NSAID damage or for IBD-type symptoms tend to see some of the clearest responses. The interstitial cystitis data, while a different condition, reinforces BPC-157's mucosal healing capacity, with patients reporting improvement as early as 2 weeks post-treatment.

For mood and well-being: some users report a subtle but noticeable improvement in baseline mood, stress resilience, and motivation, especially at higher doses or with injection. This is consistent with the dopamine and serotonin modulation seen in the animal literature but is one of the less predictable effects across individuals. Some users also report a temporary dip in mood when discontinuing, likely related to neurotransmitter levels reverting to baseline.

Side effects & risks:

Generally very well tolerated. No serious adverse events have been reported across any of the three human studies (roughly 30 participants total), and animal toxicology data shows no organ toxicity even at very high doses. No lethal dose has been identified.

Nausea is the most commonly reported side effect, more often with the oral route and at higher doses. Taking it on a fully empty stomach can worsen this, a small amount of food beforehand can help without significantly reducing absorption.

Injection site reactions: redness, mild swelling, and tenderness are common with subcutaneous administration. Rotating injection sites reduces this.

Headache and lightheadedness are occasionally reported, likely related to nitric oxide and vasodilatory effects, particularly at higher doses.

Vivid dreams are reported anecdotally by a subset of users, possibly related to serotonergic or dopaminergic modulation.

Mood changes on discontinuation: because BPC-157 modulates dopamine and serotonin, some users report a subtle mood dip when stopping abruptly, especially after longer or higher-dose protocols.

Active cancer or tumour history, avoid. The same pro-angiogenic mechanisms that accelerate tissue healing could theoretically support tumour vascularisation and growth. The evidence is animal-based and the real-world risk is unknown, but the mechanism is real.

Pregnant or breastfeeding, avoid. There is no safety data in these populations.

Source quality matters. BPC-157 is unregulated, and product quality varies enormously. Contamination, inaccurate dosing, and outright fakes are real risks with grey-market suppliers. Always look for a recent third-party Certificate of Analysis (COA) confirming purity and accurate concentration.

WADA prohibited. BPC-157 is banned under the S0 (Unapproved Substances) category of the WADA Prohibited List. This applies in and out of competition across all WADA-signatory organisations including UFC, NFL, MLB, and NCAA. There is no Therapeutic Use Exemption available for it. If you compete in tested sports, this is a hard no.

BPC-157 is not approved for human use by any regulatory body. In 2023 the FDA classified it as a Category 2 bulk drug substance, restricting compounding pharmacies from preparing it. In February 2026, HHS indicated it would be reclassified back to Category 1, restoring access through licensed compounding pharmacies with a prescription, though the official updated list has not been published yet.